Balyasny Asset Management
PLX icon

Balyasny Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Balyasny Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-76,063
Closed -$195K – 3235
2025
Q1 		$195K Buy
+76,063
New +$182K ﹤0.01% 2595
2024
Q3 		– Sell
-13,299
Closed -$15.6K – 3070
2024
Q2 		$15.6K Buy
+13,299
New +$15.7K ﹤0.01% 2482

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Balyasny Asset Management's PLX Position: Q2 2025 in Review

Balyasny Asset Management sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 76,063 shares — an estimated $195K sold.

Balyasny Asset Management first reported a position in PLX in Q2 2024 and held it in 2 quarters. The position peaked at $195K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Balyasny Asset Management reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 76,063 Protalix BioTherapeutics shares in Q2 2025, an estimated $195K.
  • Balyasny Asset Management first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 2 quarters.
  • Balyasny Asset Management's Protalix BioTherapeutics position peaked at $195K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.